Adverse events associated with MMR vaccines in Japan.
The largest nationwide active surveillance of four Measles-Mumps-Rubella (MMR) vaccines was conducted in Japan. A total of 1255 pediatricians actively participated in the study, which comprised 8.6% of all members of the Japanese Pediatric Society. The total number of registered recipients of MMR vaccines was 38 203. They were arbitrarily given one of the MMR vaccines produced by three makers (Takeda, Osaka city, Kitasato Minato-ku. Tokyo and Biken Suita city, Japan) or the standard MMR vaccine made of designated strains (Kitasato's measles-AIK-C, Biken's mumps-Urabe Am9 and Takeda's rubella-To336) produced by Takeda, Kitasato and Biken and were observed for 35 days. The rates of virologically confirmed aseptic meningitis per 10,000 recipients were 16.6, 11.6, 3.2 and 0 for the standard MMR, Takeda MMR, Kitasato MMR and Biken MMR vaccines, respectively. The incidence of convulsions between 15 and 35 days was the highest with the standard MMR vaccine and the incidence of fever associated with vomiting occurring between 15 and 35 days (symptoms relevant to aseptic meningitis) were also the highest with the standard MMR vaccine. The incidence of parotid swelling was the lowest with Takeda MMR vaccine. This surveillance revealed that incidences of aseptic meningitis after administration of the standard MMR vaccine and of Biken MMR vaccine were different. This posed questions about the manufacturing consistency of the Urabe Am9 mumps virus vaccines. On the other hand, the National Institute of Health found that the biological characteristics of the Urabe Am9 mumps virus contained in the standard MMR vaccine and in the Biken MMR vaccine were different. The Biken Company reported that the mumps vaccine in the standard MMR vaccine was a mixture of two Urabe Am9 mumps vaccine bulks; one identical to that contained in the Biken MMR vaccine and the other produced by a different manufacturing process.
Kimura
M
M
School of Medicine, Tokai University, Isehara, Japan.
Kuno-Sakai
H
H
Yamazaki
S
S
Yamada
A
A
Hishiyama
M
M
Kamiya
H
H
Ueda
K
K
Murase
T
T
Hirayama
M
M
Oya
A
A
Nozaki
S
S
Murata
R
R
D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D005260:Female; D006801:Humans; D015994:Incidence; D007223:Infant; D007564:Japan / Q000453:epidemiology; D008297:Male; D008458:Measles Vaccine / Q000008:administration & dosage / Q000009:adverse effects*; D022542:Measles-Mumps-Rubella Vaccine; D008582:Meningitis, Aseptic / Q000139:chemically induced* / Q000453:epidemiology; D009108:Mumps Vaccine / Q000008:administration & dosage / Q000009:adverse effects*; D010309:Parotitis / Q000139:chemically induced* / Q000453:epidemiology; D011358:Product Surveillance, Postmarketing; D012306:Risk; D012411:Rubella Vaccine / Q000008:administration & dosage / Q000009:adverse effects*; D012640:Seizures / Q000139:chemically induced* / Q000453:epidemiology; D017778:Vaccines, Combined / Q000008:administration & dosage / Q000009:adverse effects
D008458:Measles Vaccine; D022542:Measles-Mumps-Rubella Vaccine; D009108:Mumps Vaccine; D012411:Rubella Vaccine; D017778:Vaccines, Combined